Explore our Website
The Knowledgebase is an online resource where you can search for information about allergy.
Around one third of the UK population (approximately 19 million people) will develop an allergy at some time in their lives.
Join us as a member of the Anaphylaxis Campaign today and help us to raise the profile of severe allergy and support those who live with life threatening allergies.
Topics of Interest
We have developed a comprehensive guide for employees and employers to help people with severe allergies at work, including an adult allergy action plan. Read more…
Our Support Groups are organised by our friendly volunteers, and are the perfect chance to meet other people living with severe allergies in your local area. Read more…
Every school is likely to have at least one pupil who is severely allergic to a type of food, and many schools will have more. Read more…
Please donate today to help us provide free services for people in need of advice and support
20th January 2021
We are saddened to learn of the tragic death of Ellen Raffell, aged 16, who sadly died on 31st October 2019. We would like to offer our deepest sympathies to her family at this difficult time. Following the inquest on Monday 18th January 2021. It has been reported that Ellen went into cardiac arrest which […]
8th January 2021
Have they taken part or are they taking part in a peanut protein powder clinical trial? Acaster Lloyd Consulting are looking for participants to take part in a research study about caregivers’ and children’s experiences of an oral peanut protein powder (immunotherapy) treatment. What does it involve? This study will involve completing an online survey […]
7th January 2021
Aimmune Therapeutics’ PALFORZIA® has been approved by the European Commission as a treatment for peanut allergy. The European Commission (EC) has approved PALFORZIA® for the treatment of peanut allergy, making it the first treatment for the condition. Produced by Aimmune Therapeutics, a Nestlé Health Science Company, PALFORZIA is indicated in patients aged four to 17 […]
6th January 2021
Allergy Therapeutics PLC – Sussex-based biotechnology firm focused on allergy vaccines – Initiates peanut allergy biomarker study with Imperial College London to confirm potential of novel peanut vaccine candidate. The study aims to evaluate the novel virus like particle based peanut allergy vaccine candidate, to confirm its hypoallergic potential and its potent immune response. Submission […]